Anticraving medications for relapse prevention: A possible new class of psychoactive medications

American Journal of Psychiatry

Volumn 162, Issue 8, 2005, Pages 1423-1431

  O'Brien, Charles P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACAMPROSATE; ALCOHOL; AMFEBUTAMONE; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRENORPHINE; CANNABINOID; CANNABINOID 1 RECEPTOR; COCAINE; DIAMORPHINE; DISULFIRAM; DOPAMINE; METHADONE; MODAFINIL; MU OPIATE RECEPTOR; NALTREXONE; NICOTINE; ONDANSETRON; OPIATE; PROPRANOLOL; PSYCHOTROPIC AGENT; RIMONABANT; TOPIRAMATE; VIGABATRIN;

ALCOHOLICS ANONYMOUS; ALCOHOLISM; CENTRAL NERVOUS SYSTEM; CIGARETTE SMOKING; COCAINE DEPENDENCE; COGNITIVE DEFECT; DRUG APPROVAL; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HEROIN DEPENDENCE; HUMAN; INFANTILE SPASM; MENTAL HEALTH CARE; METHADONE TREATMENT; OPIATE ADDICTION; OUTPATIENT CARE; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RELAPSE; REVIEW; SCOTOMA; SEIZURE; SMOKING CESSATION; TOBACCO DEPENDENCE; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ALCOHOLISM; BEHAVIOR, ADDICTIVE; BUPROPION; COCAINE-RELATED DISORDERS; DISULFIRAM; HUMANS; NALTREXONE; NICOTINE; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; RECURRENCE; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER;

EID: 23344436673     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.8.1423     Document Type: Review

References (70)

1. Lawental E: Ultra rapid opiate detoxification as compared to a 30-day inpatient detoxification program - a retrospective follow-up study. J Subst Abuse 2000; 11:173-181
2. Gerra G, Zaimovic A, Giusti F, Di Gennaro C, Zambelli U, Gardini S, Delsignore R: Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat 2001; 21:11-17
3. McLellan AT, Lewis DC, O'Brien CP, Kleber HD: Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284:1689-1695
4. Carroll KM, Rounsaville BJ, Gawin FH: A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. Am J Drug Alcohol Abuse 1991; 17:229-247
5. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (eds): Combining Medication and Psychosocial Treatments for Addiction - The Brenda Approach. New York, Guilford, 2001
6. Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997; 58:7-29
7. Crits-Christoph PL, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, Muenz LR, Thase ME, Weiss RD, Gastfriend DR, Woody G, Barber JP, Butler SF, Daley D, Salloum I, Bishop S, Najavits LM, Lis J, Mercer D, Griffin ML, Moras K, Beck S: Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999; 56:493-502
8. Meyer R, Mirin S: The Heroin Stimulus. New York, Plenum, 1979
9. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, O'Brien CP: Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 1997; 14:529-534
10. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Enrich EW (Vivitrex Study Group): Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293:1617-1625
11. Kranzler HR, Wesson DR, Billot L (Drug Abuse Sciences Naltrexone Depot Study Group): Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004; 28:1051-1059
12. Volpicelli JR, Alterman AJ, Hayashida M, O'Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-880
13. Anton RF, Moak DH, Latham PK: The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996; 53:225-231
14. Tiffany ST: Cognitive concepts of craving. Alcohol Res Health 1999; 23:215-224
15. Altshuler HL, Phillips PA, Feinhandler DA: Alteration of ethanol self-administration by naltrexone. Life Sci 1980; 26:679-688
16. Volpicelli JR, O'Brien CP, Alterman AI, Hayashida M: Naltrexone and the treatment of alcohol dependence: initial observations, in Opioids, Bulimia, Alcohol Abuse and Alcoholism. Edited by Reid LB. New York, Springer-Verlag, 1990, pp 195-214
17. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B: Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49:881-887
18. Gonzales RA, Weiss F: Suppression of ethanol-reinforced beh avior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 1998; 18:10663-10671
19. Roberts AJ, McDonald JS, Heyser CJ, Kieffer BL, Matthes HW, Koob GF, Gold LH: mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 2000; 293:1002-1008
20. Gianoulakis CB, Krishnan B, Thavundayil J: Enhanced sensitivity of pituitary-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 1996; 53:250-257
21. King AC, Volpicelli JR, Frazer A, O'Brien CP: Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl) 1997; 129:15-22
22. Volpicelli JR, Clay KL, Watson NT, O'Brien CP: Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 1995; 56:39-44
23. O'Malley SS, Jaffe AJ, Rode S, Rounsaville BJ: Experience of a "slip" among alcoholics treated with naltrexone or placebo. Am J Psychiatry 1996; 153:281-283
24. Liu X, Weiss F: Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 2002; 22:7856-7861
25. Rohsenow DJ, Colby SM, Monti PM, Swift RM, Martin RA, Mueller TI, Gordon A, Eaton CA: Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000; 24:1542-1549
26. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK: Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25:1634-1647
27. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP: Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999; 156:11-18
28. 2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 2004; 161:1783-1789; correction, 161:2344
29. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK: Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156:1758-1764
30. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek J: Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 2002; 160:19-29
31. Sinha R, Catapano D, O'Malley SA: Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology (Berl) 1999; 142:343-351
32. Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF: Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988; 29:1207-1211
33. Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O'Brien CP: A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 1998; 15:281-289
34. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP: Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54:737-742
35. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B: A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35:587-593
36. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, Meyer JM, Toomey R, Faraone SV, Eaves L: Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 1996; 67:473-477
37. Higuchi S, Matsushita S, Muramatsu T, Murayama M, Hayashida M: Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese. Alcohol Clin Exp Res 1996; 20:493-497
38. Schuckit MA: Low level of response to alcohol as a predictor of future alcoholism. Am J Psychiatry 1994; 151:184-189
39. Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O'Malley SS: Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64:1044-1053
40. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR: Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10:258-268
41. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B: Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49:599-608
42. Bohman M, Cloninger R, Sigvardsson S, von Knorring AL: The genetics of alcoholisms and related disorders: J Psychiatr Res 1987; 21:447-452
43. Lesch OM, Walter H: Subtypes of alcoholism and their role in therapy. Alcohol Alcohol 1996; 31:63-67
44. Gianoulakis C: Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psychiatry Neurosci 2001; 26:304-318
45. Bond C, LaForge K, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L: Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95:9608-9613
46. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A: The mu-opioid receptor gene polymorphism (AII8G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002; 26:106-114
47. Hernandez-Avila C, Wand G, Luo X, Gelernter J, Kranzler HR: Association between the Cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 2003; 118:60-65
48. Oslin DW, Berrettini W, Kranzler H, Pettinati HM, Gelernter J, Volpicelli J, O'Brien CP: A functional polymorphism of the mu opioid receptor gene is associated with naltrexone response in alcohol dependent patients. Neuropsychopharmacology 2003; 28:1546-1552
49. Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgansberger W, Schadrack J: The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001; 40:749-760
50. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Widemann K: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60:92-99
51. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I: Disulfiram treatment of alcoholism: a Veterans Administration Cooperation Study. JAMA 1986; 256:1449-1455
52. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ: Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361:1666-1667
53. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J: Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled study. JAMA 2000; 284:963-971
54. Ferry LH, Pettis JL, Loma L, Burchette RJ: Evaluation of bupropion versus placebo for treatment of nicotine dependence, in 1994 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, pp 199-200
55. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schurman K, Dieben J, Vanderschuren LJ, Schoffelmeer AN: A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001; 7:1151-1154
56. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA: Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003; 167:103-111
57. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G: Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997; 132:104-106
58. Robinson TE, Berridge KC: Incentive sensitization and addiction. Addiction 2001; 96:103-114
59. Anthony JC, Warner LA, Kessler RC: Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Experimental Clin Psychopharmacol 1994; 2:244-268
60. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ: Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61:264-272
61. McCance-Katz EF, Kosten TR, Jatlow P: Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 1998; 52:27-39
62. Vaccari A, Saba PL, Ruiu S, Collu M, Devoto P: Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol 1996; 139:102-108
63. Dackis CA, O'Brien CP: Glutamatergic agents for cocaine dependence. Ann NY Acad Sci 2003; 1003:1-18
64. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP: A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30:205-211
65. Kalivas PW, McFarland K, Bowers S, Szumlinski K, Xi ZX, Baker D: Glutamate transmission and addiction to cocaine. Ann NY Acad Sci 2003; 1003:169-175
66. Kampman KM, Volpicelli JR, Mulvaney F, Alterman Al, Cornish J, Gariti P, Cnaan A, Poole S, Muller E, Acosta R, Luce D, O'Brien CP: Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2002;63:69-78
67. Kampman KM, Pettinati HM, Lynch KG, Dackis C, Sparkman T, Weigley C, O'Brien CP: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75:233-240
68. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP, Dewey SL: The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol Biochem Behav 2001; 68:291-299
69. Brodie JD, Figueroa E, Dewey SL: Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003; 50:261-265
70. Shoptaw S, Yang X, Rotheram-Fuller EJ, Hsieh YC, Kintaudi PC, Charuvastra VC, Ling W: Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003; 64:1440-1448